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WATSON: Will the hearing please come to 
4 
5 The members of the public and those persons of the 
6 press, thank you for corning out. 
7 In Decerni)er of last year, eight people were injured 
8 Los les using eye drops, found to contain bleach or acid. 
9 The product in question was a very popular nonprescription 
10 drug. Less than a year later, Tylenol, another popular over-
11 the-counter drug product, was tampered with in Chicago, and 
12 that incident resulted in a number of deaths. We now understand 
13 that a similar case involving Tylenol has occurred in northern 
14 California. The tragic resul~ of what must be described as a 
15 diabolical scheme are, at best, a very sick plot for motives 
16 yet to be determined, also have had the effect of undermining a 
17 very basic principle about product supply and purchasing systems 
22 
23 
The type of tampering that involved Visine less than 
a year ago Tylenol today has undercut the public's trust in 
gr of products purchased for personal ingestion. 
Assemblyman Torres and I have called this Joint House 
heari of Legislature to bring formation to the public 
about is most serious problem. The public's trust must be 
restored. We will examine methods to increase protection to the 
25 consumer regard to ingestable products which hopefully will 
26 lp us bui the trust our citizens must have in the American 
27 marketplace. 
Assemblyman Torres and I are developing legislative 
ls for cons the next islative sess to 
2 
3 
4 
5 
7 
8 
faci ss. 
islation I will propose wi 
counter products marketed in California 
that all 
prov to 
the consumer in tamper-resistant or tamper-evident packaging. 
I also is ion that wou require State 
of Consumer Affairs to undertake a study that wou 
resu recomrrtendations to the islature on feasible me 
9 for the packaging and sale of food and drug products which will 
10 afford the greatest protection to the public from alteration 
se various products. 
The hearing th morning will not a debate on 
13 these sues. We're meeting to bring the most current andre 
14 vant information to the public on this problem and to discuss 
15 ods for reducing the product purchasing risk to the consum-
16 ers. 
We do have a set agenda of speakers who are from 
industry and from these various departments, and we will open 
to 
I'd like to introduce some of people who will 
s us .the:.As , and there will be members 
Senate be arr as we go on into the session. 
As 
Assemblyman 
Felando on my right~ on the far right, 
I was going to call you Mayor -- Elder, and 
As 
He a 
I'd 1 to introduce the Cha of the 
of the Assembly, Asserrblyman Art Torres. 
ASSEMBLY!~N TORRES: Thank you, Madam Chairperson. 
I th today we're 
1 lie policy making, a chal wh 
balancing the interest of the consumers, of drug companie~ 
3 retai s and the impact that any legislation or public policy 
4 11 have upon the industry. At the forefront of that is how 
5 we begin to deal effectively with what I call drugstore 
6 terrorists, terms of dealing with the responsibilities and 
7 the responsibilities under the law. Any legislation that we 
8 come up with, I think, therefore, has to include not only 
9 packaging proposals in terms of what the drug companies can-do 
10 to insure that the consumer is aware when drugs have been 
11 tampered with in the marketplace, but also, importantly, a clear 
12 message to these types of terrorists that we essentially call 
13 criminals will have on notice, that the Legislature in 
14 California in conjunction with reasonable public policies at the 
15 Federal level, will work together not only for state sanctions 
16 against individuals who tamper with drugs at the expense of 
17 consumers, but also, importantly, to cover interstate actions 
18 that we can work with at the Federal Congress as well in 
25 
26 
1 c 
of the 
a public policy agenda. 
Therefore. I hope this hearing will bring us a 
r to some of those ideas, a little closer to that 
hopeful provide us with some answers in terms 
with the clear understanding that no legislation 
can ever prevent a tragedy. But at least we can make that 
Thank you. 
CHAIRPERSON WATSON: Thank you, Assemblyman Torres. 
We're going to follow the agenda. We have made 
c 
5 
6 
7 
s, of wh 
I'd 1 
are cop s 
to call at 
the 
t C ibornea 
1 ctor of the Food and Drug Administration. Mr. 
? 
MR. CLAIBORNE: Good morning. 
CHA WATSON: morning. 
MR. CLAIBORNE: I have a prepared statement that I 
1 the has seen copies. 
CF~IRPERSON WATSON: Senators, you have copies in 
packet. 
MR. CLAIBORNE: I am here today to discuss with you 
events surrounding the recent contamination of Extra-
13 Tylenol capsules and to share with you our thoughts and concerns 
14 regarding th tragic event. We have received excellent 
15 cooperation from the State and local authorities, and industry, 
16 who have responded swiftly and effectively to this emergency. 
17 Based on the report~of the deaths in Chicago by a 
cook County Medical examination -- examiner on September 30, 
manu of Tylenol, McNeil Consumer Products 
Fort Wa ington, Pennsylvania diately removed 
lots from tplace which linked to the deaths. 
In Ch area, all Extra-Strength Tylenol capsules 
23 were withdrawn. 
24 At 
s s re 
same time, the Food and Drug Administration 
ses on 30 and october 1 advising 
consumers not to use Extra-Strength Tylenol until circumstances 
the deaths could be clarified. Additionally, FDA 
Extra-Strength 
Dur the next four days, over a mi and a half 
2 Tylenol capsules were sampled and tested. None of the capsules 
3 outs the Chicago area showed cyanide contamination. In 
4 add ion, plants where the lots involved had been produced 
5 were inspected to insure that the contaminant had not been 
6 introduced into the product during the manufacturing process. 
7 For a number of reasons, it was concluded that the contamination 
8 was the result of tampering after the capsules had been shipped 
9 to distribution points and, most likely, after they had reached 
10 the retail shelves. These factors included: the fact that the 
11 only cases of injury and death associated with cyanide-contami-
12 nated capsules were in the Chicago area and all had occurred 
13 within a week's time. The control numbers directly associated 
14 with the injuries and deaths were produced in two widely 
15 separated plants: and the fact that there was no uniformity in 
16 the amount of cyanide present in the capsules that were 
TI analyzed. 
18 FDA also checked reports of deaths or illnesses in 
19 areas other than Chicago and none proved to be related to 
20 1. FDA issued another press release on October 4 to 
21 prov is updated information and to continue to advise 
22 use of nonprescription Tylenol capsules. 
As authorities continued to investigate the cyanide 
24 isoning deaths in the Chicago area, a report of Tylenol-relat-
25 ed 1~ ss involving a California man was received by FDA late 
26 on Monday evening, October 4, 1982. Although the man recovered, 
subsequent analysis of the Extra-Strength Tylenol capsules he 
n revealed the presence of strychnine. At this time, 
2 Extra-Strength Tylenol, s were notified nationwide on 
3 October 5 by the manufacturer to withdraw both Extra and 
4 Strength Tylenol capsules from their shelves. FDA also 
5 issued another press release on that date summarizing McNeil's 
6 announcement regarding the Oroville situation and restating its 
7 warning to consumers to avoid Extra-Strength and Regular 
8 nonprescription Tylenol capsules nationwide. 
9 These events have, quite understandably, generated 
concern about packaging integrity and product security. At the 
11 suggestion of FDA, the Proprietary Association, a trade 
association which represents a large number of nonprescription 
13 drug manufacturers, agreed to organize an industry task force 
14 to address this problem and immediately established the Joint 
15 Committee on Product Security. Commissioner Hayes and key FDA 
officials met with the Committee on October 5 to explore 
17 to improve product packaging so as to discourage tampering. 
Further, an expert technical subcommittee was appointed 
to develop standards for tamper-resistant packaging. This sub-
20 committee, which held its first meeting on October 7, will 
21 to meet regularly until develops measures to insure 
integrity, or at least to insure that containers 
tampered with 11 easi recognized. An integral 
24 part of these discussions has been the availability of 
25 necessary packaging materials, machinery and equipment and the 
need to 
27 
into place any new requirements that are agreed 
addition, ind s have been 
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7 
s s. 
2 Meanwhi , the ne to develop regulations to 
3 implement the packaging requirements that will ultimately be 
decided upon is obvious. Of concern to us has been the develop-
5 ment of State and local laws or proposals to require some form 
6 of t r-resistant packaging. 
7 These laws or proposals are well-intentioned actions 
8 in the face of this tragic situation. It is important, however, 
9 at there not be conflicting laws affecting nationally 
10 distributed products in such a way that it is impracticable to 
11 market such products. Therefore on October 6th, Secretary of 
12 Health and Human Services Richard Schweiker requested the FDA to 
13 in immediately drafting an emergency regulation that would 
14 require some sort of tamper-resistant package for nonprescript 
15 drugs. The Secretary went on to say that the Federal Government 
16 should play a predominant role in the development of laws or 
17 regulations to mandate tamper-resistant packaging. This would 
18 bring about uniform, consistent controls that adequately protect 
19 the public while assuring the availability of nonprescription 
20 drug products nationwide. 
21 FDA currently possesses the legal authority to 
22 regulations governing the design of containers to dis-
23 courage or indicate the occurrence of tampering. Specifically, 
24 section SOl(a) (2) (B) of the Federal Food, Drug, and Cosmetic 
25 
26 
orizes FDA to issue good manufacturing practice regula-
t for drug products. 
Good Manufacturing Practices Regulations, or GMPs, 
are those measures that manufacturers take to assure that.their 
v 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
19 
20 
assure 
is 
s are of adequate quality, including measures to 
products remain of adequate quality throughout 
of distribution. This GMP authority has been used to 
drug containers to guard against foreseeable external 
that could cause product deterioration or contamination. 
ion was not originally intended to cover tampering. 
Tampering has been uncommon and sporadic, and has therefore not 
been considered until now to be the type of threat to product 
integrity for which an industry-wide response is necessary. 
But, light of the recent events in Chicago and Oroville, it 
clear that good manufacturing practices should now include 
the use of tamper-resistant packaging to discourage or indicate 
the occurrence of tampering. Such packaging is necessary to 
assure that OTC drug products meet Federal requirements for 
safety, quality and purity at the time of purchase by the 
ultimate consumer. 
It must be recognized that the initiatives described 
above will not happen overnight. It is going to take some time 
to rmine the appropriate type of packaging to use, to 
implement the accom~anying regulations, to get the 
nt in place in the plants and to begin marketing these 
s. It ould also be emphasized that a tamper-proof 
is not feasible. Today, there are thousands of OTC 
s available to individual consumers. We can only hope to 
the packaging procedures for these products by 
more resistant to tampering of any sort. I want to 
assure you that Secretary Schweiker and Dr. Hayes will give this 
the highest pr 
t 
0 
1 
it of 
our exist 
ctor to 
consumers 
n sense of 
1 council on Pat 
wh 
re 
th, 
1 
s 
scr 
tore 
mov 
ct 
11 
il 
c se 
to 
qu 
pub 
to 
a rsona 
awareness in is area. 
1 var 
counci • 
s, 
us a our 
s sore 
nee. I can 
to 
is concludes my prepared test I 11 
t answer questions you may have. 
CF~IRPERSON WATSON: Yes, there are quest 
1. 
Assemblyman Torres? 
ASSEMBLY1~N TORRES: Yes. Under Section 501 
d, icated that that section was not c 
regu to issued. is ? 
2 Y~. CLAIBORNE: Well, the intent of 
3 was to that the manufacturing process was such at 
4 cts wh had a problem, such as light-sensitive, heat-
5 sens , that kind·of thing, would be protected by the packag-
6 om the manufacturing point to the point of sale. 
7 ASSEMBLYMAN TORRES: So, in other words, what we 
8 a situation where the -- where the FDA could have 
9 ided some direction in the area of not tamper-proof because 
we know that nothing is going to be tamper-proof, but at least 
we have is some vitamins today or some other drug products 
re there a seal on that bottle, the consumer, given 
fact that he or she must aware in mo9t instances of what's go 
14 on whatever they put into their bodies, would at least have 
15 a not that the package itself had been tampered with even 
though 
that a 
to 
would not be tamper-proof. 
Why has not the FDA moved in that direction to 
drug products sold 6n the market might prove to be a 
i n and adults? 
. CLAIBORNE: As I said in my prepared statement, 
contamination and r of products has 
not tragic resu we've 
on that basis it has been concluded 
is no reason or need for an industry requirement. 
TORRES: was it the Federal agency react-
o ting and economic demands of an industry to 
of protection to be provided when there are other 
v amin products on the market today that have that seal 
6 
? 
MR. CLAIBORNE: I'm not qu sure I 
ASSEMBLYMAN TORRES: Was the issue of money 
than the ic incidents? 
to 
MR. CLAIBORNE: No, the issue was the availability of 
consumer at the least cost, and as I said, the 
7 events heretofore just did not indicate that there was a need. 
8 ASSEMBLYMAN TORRES: All right. In your opinion do 
9 you think that there is a reason why drug companies use capsules 
10 instead of perhaps a less tamperable tablet form? 
MR. CLAIBORNE: In my own experience I understand 
some persons cannot take -- tolerate tablets in certain medica-
tions. Therefore the tablet -- the capsule was developed. 
14 ASSEMBLYMAN TORRES: Do you feel it would be 
15 able, then, to require, for example, Federal or State regulat-
16 t wou only permit tablets to be sold rather than 
17 s to st eliminate some potential threat? 
18 MR. CLAIBORNE: I'm not sure I can go that far. 
Certa you have to consider whether the capsule is a viable 
means of rned on, and if it is in certain segments. then I 
's a need to provide kind of medication. 
ASSE~illLYMAN TORRES: Chairperson Watson has indicated 
as have I and the other members of the Assembly and Senate Hea 
tee would so indicate, that we plan to work with Federal 
auth t s in terms of delin ing regulations or at least 
statutes that ought to be in conformity. We don't want to place 
an 
i 
economic hardship on drug compan':i:es having· .to· coinply · 
rent· ing approach in every state, but at the same 
a 
we're concerned 
In 
the publ 
line, what 
sa of our constituents. 
of timetable or time 1 
s 1 Government have in mind for specific actions 
now that we have more than just sporadic incidents of tamperipg 
medication? Now that we have specific incidents of death 
occurring, now I guess the message is clear to the FDA. that 
something must be done about packaging, or at least some other 
of preventive measures. What is your time line? What i :· 
recommendations are presently being considered in this specific 
area of packaging? 
MR. CLAIBORNE: our time frame is that we would 
to have regulations in place within the next several weeks. 
13 best estimate of the industry is varied. Some firms already 
14 have what you might consider tamper-resistant packaging in place 
15 and h~ve the equipment. So there -- that response would almost 
16 be immediate. 
17 ASSEMBLYMAN TORRES: Which are those terms? 
MR. CLAIBORNE: I cannot tell you offhand, sir. 
In other instances there's a question of deciding 
of packaging is necessary for that product getting the 
necessa ipment and getting the necessary materials. That 
several months for the industry to do it. cou 
ASSEMBLYMAN TORRES: And in terms of regulations 
ing from the Federal Drug Administration, you said a 
of weeks that you could expect some action so that we 
have some direction on the State and local level as to 
our options ought to be? 
MR. CLAIBORNE: My information is within the next 
several we ct to have some 
2 ASSEMBLYMAN TORRES: Before November 2nd? 
3 MR. CLAIBORNE: I'm not sure 6f the exact date, sir. 
4 ASSE~~LYMAN TORRES: Thank you, madam. 
5 CHAIRPERSON WATSON: Just to follow up with 
6 Assemblyman Torres, it is our intent to propose a piece of 
7 legislation. However, we're not going to be specific as to what 
8 the tamper-proof processing should be. our concern -- my 
9 concern is at in the State of California is that we prohibit 
10 the sale of those over-the-counter drug items and some of the 
11 non-drug items without the tamper-proof packaging. We'd want 
12 to reduce the risk to our constituents here in the state and 
13 we'd want to move rapidly because we do have the largest popula-
14 tion in the country and we do have people who come here from 
15 other areas of the world who aren't as sophisticated in terms of 
16 these ent medicines that they can buy over the counter. So 
17 we want to move in a rapid way. 
18 We will be in touch with FDA and with the ad hoc 
19 corrmittee so that whatever we finally introduce will be in line. 
20 But our concern is time. 
24 
25 
26 
As 
concerns th 
Are there other questions from the panel? Yes, 
Fe lando? 
ASSEMBLYMAN FELANDO: You addressed the packaging 
morning. What laws, if any, are on the Federal 
to tampering of these products? 
MR. CLAIBORNE: There's no specific Federal law that 
I'm aware of that speaks to tampering of food, drug and cosmetic 
cts. In , as I said, through the good manufacturing 
s can s to 
d such a way that external 
affect the intent there is to al with products 
have light resistance, heat resistance~ mo 
5 not specifically for tampering. 
6 ASSEMBLYMAN FELANDO: Then you as the Federal 
7 sentat , what would you suggest as the barest m~nimum 
8 s for people -- persons that tamper with drugs, 
9 r they be prescription or nonprescription? 
MR. CLAIBOru~E: I'm afraid that recommendations on 
s for someone who tampers out of the realm of 
rtise. My business is the hea of the consumers in 
the productst not the overt tampering. I jl,lst don• 
14 that kind of --
15 ASSEMBLYMAN FE LANDO: I ink it's the purpose of 
16 is 'swell-founded and I think it's good nt 
17 to s and talk about packaging.· However, I believe 's 
18 re ility of this committee also to consider facts that 
se drugs over-the-counter items are not tampered wi 
If re is an 1 involved with the 
was an inv with s, 
1 invo d bl ing of 
committee shou also address that part 
he s crime and ss the fact that the pen a s 
so severe and the should be so strict that 
certa discourage the mere thought of anybody ever' 
r a drug. 
. CIAIBORNE: If I may st that this is 
As 
statute a 
a 
I 
wou 
matte 
at 
terms of 
cr 1 statute 
WA'rSON: I wou just 
two proposed ces of 
bill that I'm 
on who to black 
Assemb 'l'orres does 
in his bill about the pen a 
sell the 
s 
s 
ASSEMBLYMAN ~~PBELL: That's just for starters 
CHAIRPERSON WATSON: But we will be 
Fe , into the area of pena s s 
As lyman Tucker? 
TUCKER: Yes. How areas 
that's d, approximately how many di 
we 
states 
or s? 
i 
CLAIBORNE: To my , on 
s uation cyanide and we 
with 
ASSEMBLYMAN TUCKER: How 
CLAIBORNE: To my knowledge, 
re to 
ASSEMBL~~N TUCKER: I was just 
Co sterday. 
r question I 
same company? 
i 
se 
two 
? 
was not 
s are a 
v 
,r.tr..R. ClAIBORNE: 
I'm not sure, sir. I 
1, 
't 
s. I'm not sure 
ink it's the same 
CHAIRPERSON WATSON: McNeil Laboratory. 
ASSEMBLYMAN TUCKER: Visine is? 
We're talking here about tamper-proof packaging. 
they rld to do, a litt steel capsule or 
16 
some ? How in the hell can we have a tamper-proof package? 
MR. CLAIBORNE: We don't think that a tamper-proof 
is possible or feasible. Rather, a tamper-resistant 
package that will clearly indicate to the consumer that that 
would 
was tampered with, that something had been done. It 
designed to discourage tampering, but I just don't 
ink it's possible to completely eliminate that. If someone is 
determined to tamper, they'll tamper. 
ASSEMBLYMAN TUCKER: Have you considered what ~;V'ould 
happen if we found contaminated antibiotics? Most of our anti-
biotics are in capsule form. Have you thought of what would 
happen if you found contaminated antibiotics? 
MR. CLAIBORNE: We've been concerned since Chicago 
ss ility of contamination of any drugs and that's 
re ing to move as ickly as we can. 
ASSEMBLYMAN 'l'UCKER: The reason I specified anti-
b s that most hospitals would be reluctant to use them, 
if that is the case -- will be the case -- do you 
in 11 be advisable or feasib to have that type of 
ion spensed from the source, the manufacturer, the 
who produce , to a vault situation where hospitals 
considered to be sa antibiotics? 
r safe 
can 
is? ould the persons 
substances at are being sold to the 
have a st several people. What should the penalty 
for ? 
CHAIRPERSON WATSON: I just want to interject 
Mr. C iborne represents Food and 
t I th we're going to have to determine the penalties, 
and I would hope that we could get into that discussion as part 
of th hearing. I think we're going to have to look at that. 
we would like to do in terms of sanctions. 
ASSEMBLYMAN ELDER: Senator Watson? 
CHAIRPERSON WATSON: Yes, Assemblyman Elder? 
ASSEMBLYMAN ELDER: Mr. Clairborne, I note in your 
title that you work for the Food and Drug Administration. Have 
15 there been occasions where, in the recent past, where food has 
16 been tampered with as well as drugs? It seems to me that food 
17 containers are perhaps, probably more, potentially more 
18 problematic on the market for lunatics than are drugs. Have 
s where foods have been tampered with, that 
O .C? .L. 
MR. CLAIBORNE: In the recent past, I don't recall 
s of being th. 
TUCKER: That happens often when you 
or mother-in-law. We know that happens. 
MR. CLAIBORNE: With respect to foods, you're right, 
~s ly problematical in dealing with food, given the wide 
var of packaging, ranging anywhere from hermetically sealed 

can certa se would, with the 
of common sense, would create a kind of tamper-res 
more difficu people to that. But 
same time we also have to be concerned with what 
s or 'COsts the consumer because certainly you have one 
son or two sons who, as a resu , are going to cause 
tremendous cost on economy of this country, and it 1 s 
to it more difficult for people to purchase propriatary 
food and things of that nature. So, you have to 
in the equation that we consider on that subject. 
CHAIRPERSON WATSON: Thank you, Mr. Claiborne. 
I'd like to call to the mike now Leona Egeland, 
f Deputy Director, State Department of Health Services, 
14 being followed by Alan Slagle with the Food and Drug Section. 
15 welcome, Miss Egeland. 
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You know, it's all well and good to address the 
13 packaging issue, and I'm all for it, but we're not going·to 
14 stop tampering until we get the penalties so severe that a 
person wouldn't even think of tampering. 
Now, see, I would start with a basic 20 years for 
anybody that would even open a package inside a store and go 
18 from there up to death if a death was involved. 
19 SENATOR CAMPBELL: Or worse. 
ASSEMBLYMAN FELANDO: Well, I have my own ideas on 
21 that, but I certainly cannot state them here. 
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DR. BERGER: Well, I wou only go to a pharmacy 
where a pharmacist was available, Madam Cha I would only 
go to a pharmacy where a pharmacist was avai le. 
CHAIRPERSON WATSON: Well, --
DR. BERGER: But I would suggest that in that regard, 
25 since it covers every product, that probably each product should 
26 have its O\~ -- on its own package the indications or the color 
27 of that drug, or whatever, and I heard morning that 
28 that was being developed. I think is 
1 since ere are 300, s. 
2 CHAIRPERSON WATSON: are s now 
3 7-11 stores, they're so s,--
4 ASSEMBLYMAN TUCKER: stores 
5 CHAIRPERSON WATSON: 're sold 1 st 
6 They're sold every place. These are not locations where 
7 are pharmacists available. 
8 So, my concern is, are you recommending that 
9 drugs are sold that these pamphlets, or at least some kind of 
10 information, be available? 
11 DR. BERGER: I think what you're suggesting 
12 with the drug itself. , But, even if a person buys a drug a 
13 drugstore -- I mean in a supermarket -- they should not sit 
14 to phone their pharmacist if they have any questions. Pharma-
15 cists are professionals and welcome the opportunity to d 
16 medications with their patients, even if they bought it some-
17 where else. 
18 CHAIRPERSON WATSON: All right, are there other 
19 questions? 
20 Thank you so very much. 
21 DR. BERGER: Thank you, ma'am. 
22 CHAIRPERSON WATSON: All right, we are going to 
23 up now -- I believe Rcberta Ritter is here representing the 
24 California Trial Lawyers Association. 
25 And, is Dr. Shore here? All right, so, Ms. Ritter 
26 will be speaking for the California Trial Lawyers. 
27 Welcome. 
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How do you feel about that? 
ly this. I 
ASSEMBLYMAN FELANDO: You would put it in a felony 
category. 
MS. RITTER: This act is done with intent. 
ASSEMBLYMAN FELANDO: Okay, thank you. I didn't 
expect that from the trial lawyers, but I thank you -- but I 
28 appreciate your answer. I agree with your answer. 
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What would California's ability to prosecute be if 
the adulteration of the product occurs outside California but 
injury occurs in California, and the adulteration is dis-
covered in california? 
MS. RITTER: The formal statute that you're talking 
about is that they would probably be able to prosecute in 
California. 
CHAIRPERSON WATSON: Under California law? 
MS. RITTER: Yeah. 
CHAIRPERSON WATSON: We do -- I want to bring -- I 
want to call attention to one of the forms that's in your 
current 
17 packet that gives/law as it relates to drugs and tampering, and 
18 we also have Mr. Pane from bench counsel to address some of the 
questions you had, Assemblyman Felando, what current law is out. 
20 Thank you, Ms. Ritter, for your testimony. We 
21 appreciate it. 
MS. RITTER: Thank you, Senator. 
23 CHAIRPERSON WATSON: All right. I'd like to call up 
24 at the current time Mr. Joe Sorbello, Supervising Inspector of 
25 the California State Board of Pharmacy. Mr. Sorbello? 
26 Apparently he's not here. 
27 Is there anyone representing 
SENATOR C&~PBELL: He's formerly a supervising 
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8 So, we feel we got a share of the 1 response. 
9 They were quiet, they were not hysterical, they were asking for 
10 good information, and we were grateful to the news media, to the 
11 FDA, that did support us with facts that we could relate to the 
public. 
13 Some of the problems that did develop were these 
14 people were not english-speaking and they did not understand 
15 what we were trying to tell them. We were telling them not to 
16 use any of the Tylenol capsules at this time. Some of them 
17 you could sense the fear because they had mailed some of these 
18 products to their loved ones in other countries and they wondere 
19 what can we do. 
20 Some of the people were very much concerned because 
21 samp s or packets of this product been sent to them with 
22 other purchases, such as feminine hygiene products, and they 
23 were wondering, will this contaminate the products should these 
24 be proved to have cyanide in them. Some of the women were 
25 pregnant and the lots that they had ingested did match the 
26 numbers that were being under surveillance. 
27 So this is a small sample of what really happened in 
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a burning sensat in mouth, and were a child, they 
would not relate this to you. 
Another observation we was the ct that so many 
people called us and told us, "You know, ever since I've taken 
Extra-Strength Tylenol capsules, I haven't slept too well. I've 
had pains in my stomach and other various symptoms." And we 
were wondering why are these people taking the drug that is not 
giving th~relief without relating it to their doctor or a 
pharmacist which we've tried to educate them to do. 
CHAIRPERSON WATSON: What can we do about this 
MRS. RAY: Well, I believe in prevention and I bel 
in education, and I'm sure we can come up with something that's 
going to at least educate the public to be informed about the 
responsibility of their own medical health care. And I'm will 
to work toward that goal. 
CHAIRPERSON WATSON: We'll be calling you--
MRS. RAY: Thank you. 
CHAIRPERSON WATSON: because we want to deal in 
the Legislature,too, with the public's education. 
Are there other questions now? 
Let me ask Dr. Slagle this: We were told by Leona 
Egeland last week at our press conference that if you discover 
Tylenol in your home, Extra-Strength or whatever, that you can 
take it back to the place from which you purchased it: is that 
correct? 
DR. SLAGLE: That's what we were advised by the 
27 company and that's what we advised in our press contacts. 
CtmiRPERSON WATSON: Yes. Now, the matter of 
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regular-strength lenol capsules. 
CHAIRPERSON WATSON: Extra-Strength and regular-
I 
3 I strength Tylenol --
4 SENATOR CAMPBELL: Capsules. 
5 DR. SLAGLE: Capsules, not --
6 CHAIRPERSON WATSON: And we're also instructing the 
7 public that if they find Tylenol in the home, they should put 
8 it in a secure place where children, animals and adults cannot 
9 get to it easily. 
10 DR. SLAGLE: Yes, this was previously, about the firs 
11 announcement that we had -- I think it was the first one, there 
12 were a lot of things happening -- said to just withhold the 
13 material, don't use it, put it away; And the stores were, at 
14 the direction of McNeil, withdrawing all their material from 
15 sale. Then, after the oroville situation, they agreed to remove 
16 the product from California. At that time we had a press 
17 release which said return it to your point of purchase. 
18 CHAIRPERSON WATSON: All right, thank you. 
19 Are there any other questions? 
20 DR. SLAGLE: I have here a copy of the announcement 
21 from this morning's Bee. It says: "We want you to replace your 
22 Tylenol capsules with Tylenol tablets and we'll help you do it 
23 at our expense." There are several options here, one of which 
24 is you can get your money back if you send the bottle 
25 SENATOR CAMPBELL: Is this the Johnson & Johnson ad? 
26 DR. SLAGLE: Yes. Well, actually, I think it's 
27 McNeil, Johnson & Johnson being the parent company of Me Neil. 
28 But it says you can get your cash refund for the 
·~ 
1 
2 
3 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
unused 
st 
s 
a re .. 
WATSON 
Are 
to come up and 
If 
telegram that we 
a statement at 
are not, we 
11 be se 
encouraging them to recomme 
their consideration of safety 
distribute that to the ss 
members do have a copy of 
Assemblyman Ivers? 
I 
? 
1 
ASSEMBLYMAN IVERS: Just one st 
re that I heard from many of 
b.at we should also include 
islation so that we don't 
ral Government 
different d ctions. 
CHAIRPERSON WATSON: Yes, our 
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leave, not on are we goi to 1 
packaging, but we're also to 
with penalties. I think we need a 
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So, please get to us, as soon as 
9 ideas for provision in the legislation. 
10 If there are no further responses or 
11 testimony, we will adjourn the hearing. 
12 This hearing is adjourned. 
13 (Thereupon the Joint Public Hearing be 
14 the Senate Committee on Health and Wel 
to 
s 
15 and the Assembly Committee on Health was 
16 adjourned at 11: 20 a.m.) 
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